ERBB2 and breast carcinoma: Recently, Paroni G. et al. showed that HER2–positive breast cancer cells were sensitive to KDM5 inhibition and KDM5 inhibitors exhibited a synergistic effect with HER2 targeting drugs, trastuzumab and lapatinib [32].